Warmly celebrate Xiamen is the official listing of Biotechnology Co., Ltd. trading

      Xiamen is positive for the Biotechnology Co., Ltd. in February 5, 2017  successfully landed on the new three board listed transactions, the  securities name: for the living creature, stock code: 839355.
      Xiamen  is a positive Biotechnology Co., Ltd. is a company dedicated to the  field of rapid diagnostic reagents, development, production and sales of  bio-tech company, owned high-tech enterprise qualification, Fujian  Province "Hundred Talents Program" Xiamen "double Hundred  plans "settled in business, is" Xiamen City, "Thirteen Five"  biomedicine and health industry development plan "focused on supporting  enterprises. The  company is located in the biomedical industry park Haicang District of  Xiamen City, built a first-class R & D center and international  standards of GMP plant, and through the national quality management  standard in vitro diagnostic reagents and EU industry quality management  system standard ISO13485 certification, with medical device  manufacturers Permits, with industrial production qualification.
      The  company has experience in working with well-known biological  pharmaceutical enterprises at home and abroad, senior R & D and  marketing managers, R & D team of scientists, including well-known  at home and abroad, with advanced technologies and projects, has  accumulated a stable production process technology and strong R & D  capabilities. The  company currently has a number of core technology patents, as of  December 2016 the company has applied for 10 patents, 9 patents  authorized, of which 4 invention patents, utility model 5, there is an  invention in the actual trial. In the meantime, the company has conducted research and development  cooperation with the Chinese Academy of Sciences and jointly established  a joint laboratory for medical diagnostic application technology to  establish a cooperation platform for research and development so as to  further ensure that the Company can quickly and effectively complete the  R & D and industrial transformation of related products.
         The  company currently carries out the project for POCT in vitro diagnostic  reagents and related equipment, has a mature immunochromatographic  technology platform, including gold immunochromatographic platform,  latex immunochromatographic platform and quantitative  immunochromatography platform. At  present, the company can produce products including 5 series of about  50 kinds of products, including hormones, infectious diseases, cancer  markers, drugs and myocardial markers and other products. The company also has launched a technology and product development  aspects of molecular diagnostics class, the introduction of thousands of  people plan to the national team of experts led by innovation, research  and development combined with microfluidic molecular diagnostic  technology platform and products, and has achieved initial results.
       Company  to "focus on diagnostic technology to enhance the quality of life" for  the purpose, committed to creating innovative technology platform for in  vitro diagnostic reagents, development of new rapid diagnostic reagents  and equipment to meet market demand, innovative spirit, and constantly  improve the level of disease detection, as Volkswagen's life and health escort.
        For  the positive creators will be successfully listed on the new board as  an opportunity to implement the sincere employment, good people, a more  open culture, more inclusive mentality, to better serve our customers,  to provide investors with better returns, to achieve a new Soar!